Figure 5.

LGALS3 positively regulates SREBP1 and negatively regulates KLF15

The SMCs used in experiments were mouse MOVAS cells unless otherwise specified (i.e., rat primary aortic SMCs in C and D). Cholesterol loading (80 μg/mL) and lentiviral transduction were performed as described in detail for Figure 1. TD139 was added (final 1 μM) 2 h prior to cholesterol loading. Data quantification for western blots: mean ± SEM, n ≥ 3 independent repeat experiments. Data quantification for quantitative real-time PCR: mean ± SD, n = 3 replicates; presented is one of two similar experiments. Statistics: ANOVA followed by Tukey test; ^#p < 0.05, ^##p < 0.01, ^###p < 0.001 (between paired bars); ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, compared with the basal condition (the first bar in each plot). (A) Effect of LGALS3 silencing on SREBP1 and KLF15 levels in MOVAS cells. SREBP1 (primer1) refers to a sequence in the C-terminal domain; SREBP1 (primer2) refers to a sequence in the N-terminal domain. (B) Effect of LGALS3 overexpression on SREBP1 and KLF15 protein levels in MOVAS cells. (C) Effect of LGALS3 silencing on SREBP1 and KLF15 protein levels in rat primary SMCs. (D) Effect of LGALS3 overexpression on SREBP1 and KLF15 protein levels in rat primary SMCs.